Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 1, 1998, Pages 248-252

  Ferone, Diego ^a   Lastoria, Secondo ^b   Colao, Annamaria ^a   Varrella, Paola ^b   Cerbone, Gaetana ^a   Acampa, Wanda ^b   Merola, Bartolomeo ^a   Salvatore, Marco ^c   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 IODO 6 METHOXYBENZAMIDE I 123; BROMOCRIPTINE; GROWTH HORMONE; OCTREOTIDE; QUINAGOLIDE; RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN C; UNCLASSIFIED DRUG; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; AMINOQUINOLINE DERIVATIVE; BENZAMIDE DERIVATIVE; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HUMAN GROWTH HORMONE; PROLACTIN; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE;

ADULT; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS ADENOMA; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; ADENOMA; ALPHA CHAIN; BLOOD; CLINICAL TRIAL; HYPOPHYSIS TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SCINTISCANNING; SECRETION;

ADENOMA; AMINOQUINOLINES; BENZAMIDES; BIOLOGICAL MARKERS; DOPAMINE AGONISTS; GLYCOPROTEIN HORMONES, ALPHA SUBUNIT; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; PITUITARY NEOPLASMS; PROLACTIN; PYRROLIDINES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 85047676361     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.1.4493     Document Type: Article

References (30)

1. Bevan JS, Webster J, Burke CW, Scanlon MF. 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 13:220-240.
2. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. 1995 Recent advances in pathology, diagnosis and management of acromegaly. J Clin Endocrinol Metab. 80:3395-3402.
3. Colao A, Ferone D, Marzullo P, et al. 1997 Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 82:318-323.
4. Yamada S, Asa SL, Kovaks K, Muller P, Smyth HS. 1989 Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay. J Clin Endocrinol Metab. 68:73-80.
5. Saccomanno K, Gil-del-Alamo P, Bassetti M, Reza-Elahi F, Spada A. 1993 In vitro detection of glycoprotein production and secretion by human nonfunctioning pituitary adenomas. J Endocrinol Invest. 16:109-115.
6. 3H)CV 205-502. Brain Res. 440:123-128.
7. Brue T, Pellegrini I, Gunz G, et al. 1992 Effects of dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab. 74:577-584.
8. Colao A, Merola B, Sarnacchiaro F, et al. 1995 Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Horm Res. 44:222-228.
9. Chiodini PG, Attanasio R, Cozzi R, et al. 1993 CV 205-502 in acromegaly. Acta Endocrinol (Copenh) 128:389-393.
10. Lombardi G, Colao A, Ferone D, et al. 1995 CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol. 132:559-564.
11. Kwekkeboom DJ, Lamberts SWJ. 1992 Long-term treatment with dopamine agonist CV 205-502 of patients with clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma. Clin Endocrinol (Oxf). 36:171-176.
12. 2 receptor imaging and measurements with SPECT. Adv Neurol. 60:494-500.
13. 2 receptor radioligand. Clin Endocrinol (Oxf). 45:755-767.
14. Colao A, Ferone D, Lastoria S, et al. 1996 Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 81:2356-2362.
15. Scillitani A, Dicembrino F, Di Fazio P, et al. 1995 In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J Clin Endocrinol Metab. 80:2523-2525.
16. 2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with TSH/PRL-producing pituitary macroadenoma. Eur J Nucl Med. 20:555-561.
17. 2-receptor imaging with dynamic I-123 iodo benzamide SPECT in healthy human volunteers. J Nucl Med. 32:1076-1079.
18. Ebersold MJ, Quast LM, Laws ER, et al. 1986 Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas. J Neurosurg. 334:246-254.
19. Harris PE, Afshar F, Coates P, et al. 1989 The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary adenomas. Q J Med New Series. 71:417.
20. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton MI. 1989 Hypopituitarism following external radiotherapy for pituitary tumors in adults. Q J Med New Series. 70:145.
21. Warnet A, Timsit J, Chanson P, et al. 1989 The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. J Neurosurg. 71:687-690.
22. de Bruin TWA, Kwekkeboom DJ, van't Verlaat JW, et al. 1992 Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab. 75:1310-1317.
23. Merola B, Colao A, Ferone D, et al. 1993 Effects of chronic treatment with octreotide in patients with functionless pituitary adenomas. Horm Res. 40:149-155.
24. Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ. 1994 Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab. 79:1416-1423.
25. Bevan JS, Burke CW. 1986 Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol (Oxf). 25:561-572.
26. Koga M, Nakao H, Arao M, et al. 1987 Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinol (Copenh). 114:595-602.
27. de Herder WW, Lamberts SWJ. 1995 Imaging of pituitary tumours. Baillieres Clin Endocrinol Metab. 9:367-389.
28. 2 receptor imaging. J Nucl Med. 37:1589-1591.
29. Pirker W, Riedl M, Luger A, et al. 1996 Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. J Nucl Med. 37:1931-1937.
30. Pirker W, Brücke T, Riedl M, et al. 1994 iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors. J Neural Transm. 97:235-244.